Abstract
A 70-year-old man presented with a firm tumor in his right breast first noticed eight years ago. The tumor had enlarged gradually and had produced an ulcer with bleeding. On physical examination, a huge tumor entirely occupied the right breast and extensively had infiltrated the chest wall. Chest X-ray and CT showed massive pleural effusion and multiple small nodular lesions in the lung. Invasive ductal carcinoma of the breast was diagnosed by incisional biopsy, confirming advanced breast cancer with lung metastases and bilateral pleural effusion (T4cN2Ml, Stage IV). Because ER and PgR levels were 110 fmol/mg and 190 fmol/mg, respectively, and because his general condition was poor, we selected medical treatment with tamoxifen (TAM). Thirty-two weeks later, the tumor had showed pronounced reduction with scarring. The patient underwent local excision of the scar tissue. The quality of life of the patient was favorably improved and no severe adverse events were observed. The tumor in the chest wall recurred two months after the end of TAM treatment, possibly because the patient did not accept continuous TAM therapy. The patient died from complications of brain metastasis 32 months after the start of TAM treatment. We report a rare case of advanced male breast cancer and on the effectiveness of continuous TAM treatment.
Similar content being viewed by others
Abbreviations
- TAM:
-
Tamoxifen
- ER:
-
Estrogen receptor
- PgR:
-
Progesterone receptor
References
Crichlow RW: Carcinoma of the male breast.Surg Gynecol Obstet 134:1011–1019, 1972.
Ciatto S, Iossa A, Bonardi R: Male breast carci- noma:Review of a multicenter series of 150cases.Tumori 76:555–558, 1990.
Bogen PI, Wong GY, Vlamis V: Current management of male breast cancer.Ann Surg 215:451–457, 1992.
Guinee VF, Olsson H, Moller T,et al: The prognosis of breast cancer in males.Cancer 71:154–161, 1993.
Moseley HS, Fletcher WS, Leung BS,et al: Predictive criteria for the selection of breast cancer patients for adrenalectomy.Am J Surg 128:143–151, 1974.
Everson RB, Lippmann ME, Thonpson EB,et al: Clinical correlations of steroid receptors and male breast cancer.Cancer Res 40:991–997, 1980.
Gupta N, Cohen JL, Rosenbaum C,et al: Estrogen receptors in male cancer.Cancer46:1781–1784, 1980.
Friedman MA, Hoffman PG, Dandolos EM,et al: Estrogen receptors in male breast cancenclinical and pathologic correlations.Cancer 47:134–137, 1981.
Cantwell BMJ, Tong D, Minton M,et al: Tamoxifen and male breast cancer.Lancet 2:582–583, 1978.
Morgan DAL, Hong A: Carcinoma of the male breast and oestrogen metabolism.Br Med 12:206, 1978.
Abele R, Alberto P, Megevand R: Carcinoma of the male breast and oestrogen metabolism.Br Med J 1:1697–1698, 1978.
Aisner J, Ross DD, Wiernik PH: Tamoxifen in advanced male breast cancer.Arch Intern Med 139:480–481, 1979.
Patterson JS, Battersby LA, Bach BK: Use of tamoxien in advanced male breast cancer.Cancer Treat Rep 64:801–804, 1980.
Rebeiro GG, Swindell R: Adjuvant tamoxifen for male breast cancer (MBC).Br J Cancer 65:252–254, 1992.
Becher R, Hoffken K, Pape H,et al: Tamoxifen treatment before orchiectomy in advanced breast cancer in men.New Engl J Med 305:169, 1981.
Tirelli U, Tumolo S, Talamini R,et al: Tamoxifen before and orchiectomy in advanced male breast cancer.Cancer Treast Rep 66:1882–1883, 1982.
Ribeiro GG: Tamoxifen in treatment of male breast carcinoma.Clin Radiol 34:625–628, 1983.
Anelli MTF, Anelli A, Tran KN,et al: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.Cancer 74:74–77, 1994.
Kraybill WG, Kaufman R, Kinne D: Treatment of advanced male breast cancer.Cancer47:2185–2189, 1981.
Pannuti F, Martoni A, Busutti L,et al: High-dose medroxy-progesterone acetate in advanced male breast cancer.Cancer Treat Rep 66:1763–1765, 1982.
Bezwoda WR, Hesdorffer C, Dansey R,et al: Breast cancer in men. Clinical features, hormone receptor status, and response to therapy.Cancer60:1337–1340, 1987.
Doberauer C, Niederle N, Schmidt CG,et al: Advanced male breast cancer treatment with the LH- RH analogue buserelin alone or in combination with the antiandrogene flutamide.Cancer72:474–478, 1988.
Lopez M, Natali M, Lauro LD,et al: Combined treatment with buserelin and cyproterone acetate in matastatic male breast cancer.Cancer72:502–505, 1993.
Sasano H, Kimura M, Shizawa S,et al: Aromatase and steroid receptors in gynecomastia and male breast carcinoma:an immunohistochemical study.J Clin Endocrino Metab81:3063–3067, 1996.
Author information
Authors and Affiliations
About this article
Cite this article
Kanoh, T., lino, Y., Horiguchi, J. et al. A case report of advanced male breast cancer with an objective response to tamoxifen treatment. Breast Cancer 7, 256–260 (2000). https://doi.org/10.1007/BF02967470
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02967470